1. Home
  2. AMBP vs IRON Comparison

AMBP vs IRON Comparison

Compare AMBP & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardagh Metal Packaging S.A.

AMBP

Ardagh Metal Packaging S.A.

HOLD

Current Price

$4.04

Market Cap

2.7B

Sector

Industrials

ML Signal

HOLD

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$66.09

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMBP
IRON
Founded
2021
2017
Country
Luxembourg
United States
Employees
6300
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AMBP
IRON
Price
$4.04
$66.09
Analyst Decision
Hold
Strong Buy
Analyst Count
7
11
Target Price
$4.39
$103.18
AVG Volume (30 Days)
1.5M
423.7K
Earning Date
04-23-2026
05-06-2026
Dividend Yield
9.78%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.22
N/A
Revenue Next Year
$2.51
$283.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.53
$30.82
52 Week High
$5.03
$99.50

Technical Indicators

Market Signals
Indicator
AMBP
IRON
Relative Strength Index (RSI) 41.37 56.53
Support Level $3.93 $57.79
Resistance Level $4.28 $69.36
Average True Range (ATR) 0.15 2.72
MACD 0.01 1.10
Stochastic Oscillator 36.67 85.90

Price Performance

Historical Comparison
AMBP
IRON

About AMBP Ardagh Metal Packaging S.A.

Ardagh Metal Packaging SA is a supplier of infinitely recyclable, sustainable, metal beverage cans and ends to brand owners. The company deals with multiple categories of products including beer, carbonated soft drinks, energy drinks, hard seltzers, juices, pre-mixed cocktails, teas, sparkling waters, and wine. Its segment includes Europe and the Americas. It derives a majority of its revenue from the Americas.

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Share on Social Networks: